Program
linzagolix
Also written as “KLH-2109”, “75 mg linzagolix tablet” and “200 mg linzagolix tablet”.
Its studies are mostly in Endometriosis · Leiomyoma · Renal Insufficiency · Hepatic Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kissei Pharmaceutical | 111 open or running | phase 3since Jun 6, 2019 | Jul 14, 2011 | Nov 2027phase 3 · NCT07015268 |
| ObsEva | 30 open or running | phase 2since May 3, 2016 | May 3, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2011First study: phase 2 study in EndometriosisNew to Kissei PharmaceuticalKissei Pharmaceutical · NCT01395940 · 20 enrolled · Japan
- Feb 12, 2012Phase 2 study in EndometriosisKissei Pharmaceutical · NCT01533532 · 100 enrolled · Japan
- Jun 25, 2012Phase 2 study in EndometriosisKissei Pharmaceutical · NCT01629420 · 20 enrolled · Japan
- May 3, 2016ObsEva's first study: phase 2 study in EndometriosisNew to ObsEvaObsEva · NCT02778399 · 328 enrolled · United States, Poland, Russian Federation and more
- May 18, 2016Phase 2 study in EndometriosisKissei Pharmaceutical · NCT02778919 · Japan
- May 20, 20192 phase 1 studiesObsEva · NCT03961932, NCT03962049
- Jun 6, 20192 phase 3 studies in EndometriosisKissei Pharmaceutical · NCT03986944, NCT03992846
- Apr 3, 20202 phase 3 studies in EndometriosisKissei Pharmaceutical · NCT04335591, NCT04372121
- Jun 27, 20222 phase 3 studies in LeiomyomaKissei Pharmaceutical · NCT05445167, NCT05440383
- Jun 3, 2025Phase 3 study in EndometriosisKissei Pharmaceutical · NCT07015268 · 288 enrolled · Japan
Ahead
- Nov 2027Primary completion: phase 3 study in EndometriosisKissei Pharmaceutical · NCT07015268
TargetBeta
“Gonadotropin-releasing hormone receptor antagonist; Gonadotropin-releasing hormone receptor antagonist”ChEMBL 37, by rule
Other programs on GNRHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Leuproliderule | Takeda | phase 4 | 39 |
| triptorelinrule | Ipsen | phase 4 | 21 |
| Goserelinrule | AstraZeneca | phase 4 | 14 |
| GnRH Antagonist SHR7280 | Jiangsu HengRui Medicine | phase 3 | 10 |
| Gonadotropin-Releasing Hormonerule | Ferring Pharmaceuticals | phase 3 | 5 |
| leuprolide mesylaterule | foresee-pharmaceuticals-co-ltd | phase 3 | 3 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07015268Endometriosis · Japan | 3 | Active, not recruiting | Kissei Pharmaceutical | Nov 2027 | 288 |
| NCT05445167Leiomyoma · Japan | 3 | Completed | Kissei Pharmaceutical | Feb 16, 2024 | 89 |
| NCT05440383Leiomyoma · Japan | 3 | Completed | Kissei Pharmaceutical | Aug 21, 2024 | 287 |
| NCT04372121Endometriosis · United States, Canada, Puerto Rico | 3 | Terminated | Kissei Pharmaceutical | Jan 8, 2021 | 30 |
| NCT04335591Endometriosis · United States, Austria, Bulgaria and more | 3 | Completed | Kissei Pharmaceutical | Sep 15, 2022 | 356 |
| NCT03992846Endometriosis · United States, Austria, Bulgaria and more | 3 | Completed | Kissei Pharmaceutical | Oct 18, 2021 | 486 |
| NCT03986944Endometriosis · United States, Canada, Puerto Rico | 3 | Terminated | Kissei Pharmaceutical | Jan 6, 2021 | 85 |
| NCT03962049Hepatic Insufficiency · United States | 1 | Completed | ObsEva | Oct 23, 2019 | 24 |
| NCT03961932Renal Insufficiency · United States | 1 | Completed | ObsEva | Jan 22, 2020 | 33 |
| NCT02778919Endometriosis · Japan | 2 | Completed | Kissei Pharmaceutical | Mar 23, 2018 | |
| NCT02778399Endometriosis · United States, Poland, Russian Federation and more | 2 | Completed | ObsEva | Apr 2018 | 328 |
| NCT01629420Endometriosis · Japan | 2 | Completed | Kissei Pharmaceutical | 20 | |
| NCT01533532Endometriosis · Japan | 2 | Completed | Kissei Pharmaceutical | 100 | |
| NCT01395940Endometriosis · Japan | 2 | Completed | Kissei Pharmaceutical | 20 |
How it is read
Names in the registry
- “KLH-2109”, 11 entries
- “75 mg linzagolix tablet”, 4 entries
- “200 mg linzagolix tablet”, 4 entries
- “Linzagolix”, 2 entries
- “OBE2109”, 1 entry
Conditions, from the studies’ own filings
- Endometriosis, 10 studies
- Leiomyoma, 2 studies
- Renal Insufficiency, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.